How much revenue does Tianjin Lisheng Pharmaceutical make?

Tianjin Lisheng Pharmaceutical reported 1.39 billion CNY in revenue for fiscal year 2025, up 4.2% from 1.34 billion CNY in fiscal year 2024. In Q1 2026 revenue was 332.28 million CNY.

Where does Tianjin Lisheng Pharmaceutical make most of its revenue?

Northern China: 42% of revenue by region in fiscal year 2025, followed by East China (23%).

What companies are similar to Tianjin Lisheng Pharmaceutical?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Fuan Pharmaceutical (Group) Co., Ltd. (300194.SZ), Kexing Biopharm Co., Ltd. (688136.SS), Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ), Jiangsu Lianhuan Pharmaceutical Co., Ltd. (600513.SS).

Tianjin Lisheng Pharmaceutical Co.,Ltd. (002393.SZ) Stock

About Tianjin Lisheng Pharmaceutical Co.,Ltd.

Tianjin Lisheng Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceutical products in China and internationally. The company offers pharmaceutical, traditional Chinese medicine, and antibiotic products in various forms, such as oral solid dosage forms, soft capsules, sterile preparations, and raw materials primarily for cardiovascular and digestive sys...

At a glance

Tianjin Lisheng Pharmaceutical reported revenue of 1.39 billion CNY for fiscal year 2025, up 4.2% from fiscal year 2024, and net income of 416.28 million CNY. In Q1 2026 (the quarter ended March 31, 2026) revenue was 332.28 million CNY, down 10.2% from a year before. Northern China was its largest region in fiscal year 2025, with 42% of revenue.

Figures from company filings; latest fiscal year ended December 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.